Evidence map›Paper›PMID 17548613›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2007

Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope.

Keri L Schaubert, David A Price, Nicole Frahm, Jinzhu Li, Hwee L Ng, Aviva Joseph, Elyse Paul, Biswanath Majumder, Velpandi Ayyavoo, Emma Gostick and 10 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Therapeutic Vaccines for the Treatment of HIV.Translational research : the journal of laboratory and clinical medicine · 2020
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Enhanced induction of HIV-specific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA.Molecular therapy : the journal of the American Society of Gene Therapy · 2010
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Keri L SchaubertKarmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
David A Price
Nicole Frahm
Jinzhu Li
Hwee L Ng
Aviva Joseph
Elyse Paul
Biswanath Majumder
Velpandi Ayyavoo
Emma Gostick
Sharon Adams
Francesco M Marincola
Andrew K Sewell
Marcus Altfeld
Jason M Brenchley
Daniel C Douek
Otto O Yang
Christian Brander
Harris Goldstein
June Kan-Mitchell

Funding

Mechanisms of Immune Activation and Disease Progression in Animal ModelsZIAAI001029 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BRENCHLEY, JASON · 2009 to 2025
$28.2M
TOXICOLOGY PROJECTG12RR008124 · NCRR · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 1992 to 2011
$20.8M
Optimizing Gag CTL Epitopes to Improve ImmunogenicityR01AI064069 · NIAID · WAYNE STATE UNIVERSITY · PI KAN-MITCHELL, JUNE · 2006 to 2010
$2.8M
Immunogenetic Study of Infectious Diseases and CancerZ01CL002118 · CLC · CLINICAL CENTER · PI MARINCOLA, FRANCESCO M · 2007 to 2008
$1.4M
Mechanisms of Immune Activation and Disease Progression in Animal ModelsZ01AI001029 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BRENCHLEY, JASON · 2008 to 2008
$455k
Intramural NIH HHS Z01 AI001029Intramural NIH HHS Z99 AI999999Intramural NIH HHS ZIA AI001029Medical Research Council G0501963NCRR NIH HHS 5G12 RR 008124NCRR NIH HHS G12 RR008124NIAID NIH HHS R01 AI 064069NIAID NIH HHS R01 AI064069
6 · The paper itself

Abstract

HLA-A2-restricted CTL responses to immunodominant HIV-1 epitopes do not appear to be very effective in the control of viral replication in vivo. In this study, we studied human CD8+ T cell responses to the subdominant HLA-A2-restricted epitope TV9 (Gag p24(19-27), TLNAWVKVV) to explore the possibility of increasing its immune recognition. We confirmed in a cohort of 313 patients, infected by clade B or clade C viruses, that TV9 is rarely recognized. Of interest, the functional sensitivity of the TV9 response can be relatively high. The potential T cell repertoires for TV9 and the characteristics of constituent clonotypes were assessed by ex vivo priming of circulating CD8+ T cells from healthy seronegative donors. TV9-specific CTLs capable of suppressing viral replication in vitro were readily generated, suggesting that the cognate T cell repertoire is not limiting. However, these cultures contained multiple discrete populations with a range of binding avidities for the TV9 tetramer and correspondingly distinct functional dependencies on the CD8 coreceptor. The lack of dominant clonotypes was not affected by the stage of maturation of the priming dendritic cells. Cultures primed by dendritic cells transduced to present endogenous TV9 were also incapable of clonal maturation. Thus, a diffuse TCR repertoire appeared to be an intrinsic characteristic of TV9-specific responses. These data indicate that subdominance is not a function of poor immunogenicity, cognate TCR repertoire availability, or the potential avidity properties thereof, but rather suggest that useful responses to this epitope are suppressed by competing CD8+ T cell populations during HIV-1 infection.

Indexed as

Amino Acid SequenceCD8-Positive T-LymphocytesCells, CulturedCross ReactionsDendritic CellsGene Products, gagHIV-1HLA-A2 AntigenHumansImmunodominant EpitopesReceptors, Antigen, T-CellT-Lymphocytes, CytotoxicGene Products, gagHLA-A2 AntigenImmunodominant EpitopesReceptors, Antigen, T-Cell

Identifiers

PMID17548613
PMCPMC2365726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.